Search Result

Results for "

Glycemic control

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (2) Bacterial (4) Biochemical Assay Reagents (2) CaSR (1) Cholinesterase (ChE) (1) Dipeptidyl Peptidase (8) Endogenous Metabolite (5) Epigenetic Reader Domain (1) Free Fatty Acid Receptor (6) Fungal (1) FXR (1) G protein-coupled Bile Acid Receptor 1 (1) GCGR (4) GLP Receptor (3) Histone Demethylase (1) Isotope-Labeled Compounds (2) Neuropeptide Y Receptor (1) p38 MAPK (1) Parasite (1) Phosphatase (1) PPAR (3) Reference Standards (4) SGLT (2)
By Research Areas:	Cancer (4) Endocrinology (1) Infection (4) Inflammation/Immunology (5) Metabolic Disease (32) Neurological Disease (1)

By Targets:

5-HT Receptor (2)

Bacterial (4)

Biochemical Assay Reagents (2)

CaSR (1)

Cholinesterase (ChE) (1)

Dipeptidyl Peptidase (8)

Endogenous Metabolite (5)

Epigenetic Reader Domain (1)

Free Fatty Acid Receptor (6)

Fungal (1)

FXR (1)

G protein-coupled Bile Acid Receptor 1 (1)

GCGR (4)

GLP Receptor (3)

Histone Demethylase (1)

Isotope-Labeled Compounds (2)

Neuropeptide Y Receptor (1)

p38 MAPK (1)

Parasite (1)

Phosphatase (1)

PPAR (3)

Reference Standards (4)

SGLT (2)

By Research Areas:

Cancer (4)

Endocrinology (1)

Infection (4)

Inflammation/Immunology (5)

Metabolic Disease (32)

Neurological Disease (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P3463

Beinaglutide 1 Publications Verification GLP-1 (human)	GCGR	Metabolic Disease Inflammation/Immunology
Beinaglutide is a human GLP-1 polypeptide that shares almost 100% homology with human GLP-1 (7–36). Beinaglutide displays does-dependent effects in glycemic control, inhibiting food intake and gastric empty and promoting weight loss. Beinaglutide has the potential for the research of overweight/obesity and nonalcoholic steatohepatitis (NASH) .

HY-150105

Icovamenib BMF-219; Menin-MLL inhibitor 21	Epigenetic Reader Domain	Metabolic Disease Inflammation/Immunology Cancer
Icovamenib (BMF-219) is a selective, orally active, irreversible Menin inhibitor. Icovamenib forms a stable and irreversible covalent bond with Menin. Icovamenib promotes selective and controlled proliferation of beta cells and improvement of beta cell function in ex vivo human islet cultures. Icovamenib enhances glycemic control in animal diabetic models. Icovamenib induces a dose-dependent enhancement in insulin secretion potentiated by the GLP-1 RA. Icovamenib can be used for the study of multiple hematologic malignancies, solid tumors, and diabetes mellitus, such as diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM) and chronic lymphocytic leukemia and type 2 diabetes .

HY-15408

Trelagliptin 1 Publications Verification SYR-472	Dipeptidyl Peptidase	Metabolic Disease
Trelagliptin (SYR-472) is a potent, orally active and highly selective DPP-4 inhibitor with an IC₅₀ of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM) .

HY-W145665

Amylose	Biochemical Assay Reagents Endogenous Metabolite	Others
Amylose is not a typical small-molecule ligand with a specific traditional receptor-binding target. It is a polysaccharide. In food science and biological systems, amylose can interact with proteins and free fatty acids through non-covalent forces like hydrophobic interactions and electrostatic interactions. For example, it can form a ternary complex with them, which is related to the structure and digestion of starch. It is widely studied in the fields of food science, carbohydrate metabolism, and is also relevant in research on controlling glycemic responses, as it affects starch digestion rate .

HY-13467

AM-1638 3 Publications Verification	Free Fatty Acid Receptor	Metabolic Disease
AM-1638 is an orally active full agonist of GPR40 (EC₅₀: 0.16 μM). AM-1638 increases the expression of antioxidant molecules (HO-1 and NQO-1). AM1638 blocks Palmitate (HY-N0830)-mediated superoxide production and ER stress. AM-1638 has antidiabetic activity and improves glycemic control in BDF mice with diet-induced obesity (DIO). AM-1638 demonstrates excellent oral bioavailability (mouse, >100%; rat, 72%; and cyno, 71%) .

HY-106539

Colesevelam hydrochloride	FXR G protein-coupled Bile Acid Receptor 1 GLP Receptor	Metabolic Disease Cancer
Colesevelam hydrochloride is an orally active bile acid sequestrant, lipid-lowering agent, and glycemic control agent. Colesevelam hydrochloride binds bile acids in the gastrointestinal tract to form nonabsorbable complexes, interrupts enterohepatic recirculation and increases fecal bile acid elimination. Colesevelam hydrochloride modulates FXR, TGR5, and Cyp7a1 activity and triggers cAMP signaling and GLP-1 release. Colesevelam hydrochloride alters hepatic lipid and glucose metabolism, suppresses hepatic glycogenolysis, reduces hepatic triglyceride and cholesterol levels, and increases LDL-C (low-density lipoprotein cholesterol) clearance. Colesevelam hydrochloride can be used for the research of type 2 diabetes mellitus, hypercholesterolemia, and alcohol-related liver disease .

HY-113075

1,5-Anhydrosorbitol 1 Publications Verification 1,5-Anhydro-D-glucitol	Endogenous Metabolite	Metabolic Disease
1,5-Anhydrosorbitol is a short-term marker for glycemic control.

HY-15408A

Trelagliptin succinate 1 Publications Verification SYR-472 succinate	Dipeptidyl Peptidase	Metabolic Disease
Trelagliptin (SYR-472) succinate is a potent, orally active and highly selective DPP-4 inhibitor with an IC₅₀ of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM) .

HY-16421

Ragaglitazar (-)-DRF 2725; NNC 61-0029	PPAR	Metabolic Disease
Ragaglitazar is a PPARα and PPARγ agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic.

HY-13967B

AMG 837 calcium hydrate 3 Publications Verification	Bacterial Free Fatty Acid Receptor	Metabolic Disease
AMG 837 calcium hydrate is an orally active, selective GPR40/FFA1 agonist with an EC₅₀ of 1.5 nM against human GPR40. AMG 837 calcium hydrate stimulates insulin secretion in a glucose-dependent manner, and effectively improves glycemic control in both normal and diabetic rodent models . AMG 837 calcium hydrate binds to the BacA protein and impairs the survival and replication of Brucella. AMG 837 calcium hydrate can be used in research related to type 2 diabetes and brucellosis .

HY-N10423

Cubebin (-)-Cubebin	Cholinesterase (ChE) Bacterial Fungal Parasite p38 MAPK	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Cubebin ((-)-Cubebin), a dibenzyl butyrolactone lignan, is an orally active AChE inhibitor. Cubebin binds to active sites of NF-κB, TNF-α, and TGF-β1 via hydrogen and hydrophobic interactions, obstructing critical residues to inhibit pro-inflammatory or renal fibrosis-related activity. Cubebin enhances p38 MAPK phosphorylation to increase tyrosinase gene expression, stimulating melanogenesis via elevated tyrosinase activity, expression, and mRNA levels. Cubebin reduces oxidative stress via enhanced endogenous antioxidant enzyme activity and inhibited lipid peroxidation, regulates lipid metabolism, improves glycemic control, and exerts renoprotective effects via reduced renal dysfunction markers and improved renal architecture. Cubebin shows antimicrobial activity. Cubebin exerts larvicidal activity against Angiostrongylus cantonensis larvae, with no cytotoxicity toward monkey or human cell lines or Caenorhabditis elegans. Cubebin can be used for the research of diabetic nephropathy, melanoma, colon adenocarcinoma, neuroangiostrongyliasis, Alzheimer’s disease (AD) and depression .

HY-139201E

Poly-D-lysine hydrobromide (MW 150000-300000) PDLHB (MW 150000-300000)	CaSR 5-HT Receptor	Metabolic Disease
Poly-D-lysine hydrobromide (MW 150000-300000) is a synthetic polymer composed of D-lysine residues and is one of the most widely used matrices in neural cell culture applications. Poly-D-lysine hydrobromide (MW 150000-300000) can be used as a non-specific cell adhesion enhancer. Poly-D-lysine hydrobromide (MW 30000-70000) is an orally active CaSR agonist peptide that indirectly activates the 5-HT₃ receptor signaling pathway, delaying gastric emptying and thereby slowing the rate at which glucose enters the small intestine and is absorbed .

HY-P10341

ZP3022	GCGR	Metabolic Disease
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .

HY-101122

LX2761	SGLT GLP Receptor	Metabolic Disease
LX2761 is an orally active, dual SGLT1/SGLT2 inhibitor with IC₅₀ values of 2.2 nM and 2.7 nM against human SGLT1 and SGLT2, respectively. LX2761 locks human SGLT1 in an outward-open conformation and blocks its putative water permeation pathway. After oral administration, LX2761 is confined exclusively to the intestinal lumen, delays intestinal glucose absorption, regulates intestinal glucose metabolism, increases cecal glucose levels, reduces cecal pH, improves glycemic control and elevates plasma total GLP-1 levels. However, LX2761 induces diarrhea in a dose-dependent manner. LX2761 can be used in diabetes-related research .

HY-13967

AMG 837 3 Publications Verification	Free Fatty Acid Receptor Bacterial	Infection Metabolic Disease
AMG 837 is an orally active, selective GPR40/FFA1 agonist with an EC₅₀ of 1.5 nM against human GPR40. AMG 837 stimulates insulin secretion in a glucose-dependent manner, and effectively improves glycemic control in both normal and diabetic rodent models . AMG 837 binds to the BacA protein and impairs the survival and replication of Brucella. AMG 837 can be used in research related to type 2 diabetes and brucellosis .

HY-100546

GSK-LSD1	Histone Demethylase	Infection Metabolic Disease Cancer
GSK-LSD1, a chemical probe, is a LSD1 inhibitor. GSK-LSD1 reduces food intake and body weight, and improves insulin sensitivity and glycemic control in mouse models of obesity. GSK-LSD1 also ameliorates NAFLD. GSK-LSD1 inhibits SARS-CoV-2-triggered cytokine release in COVID-19 PBMCs. GSK-LSD1 also inhibits cancer growth and metastasis .

HY-164870

FFAR1/FFAR4 agonist-1	Free Fatty Acid Receptor	Metabolic Disease Inflammation/Immunology
FFAR1/FFAR4 agonist-1 (compound 83) is a FFAR1/FFAR4 agonist with the EC₅₀ of 1 nM A and 4nM for FFAR1 and FFAR4, respectively. FFAR1/FFAR4 agonist-1 can be used for study of glycemic control .

HY-105074

Farglitazar GI262570; GI262570X	PPAR	Metabolic Disease
Farglitazar is a PPARγ agonist that has significant therapeutic benefits such as glycemic control in type 2 diabetic patients.

HY-NP205

Glycated Albumin (Human)	Biochemical Assay Reagents	Metabolic Disease
Glycated Albumin (Human) is an alternative marker for glycemic control. Glycated Albumin (Human) can react with glucose .

HY-15408S

Trelagliptin-13C,d3 SYR-472-¹³C,d₃	Isotope-Labeled Compounds Dipeptidyl Peptidase	Metabolic Disease
Trelagliptin-13C,d3 is a deuterated labeled Trelagliptin . Trelagliptin (SYR-472) is a potent, orally active and highly selective DPP-4 inhibitor with an IC₅₀ of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM) .

HY-P10318

SHR-2042	GLP Receptor	Endocrinology
SHR-2042 is a selective agonist of the GLP-1 receptor.SHR-2042 improves glycemic control by activating the GLP-1 receptor, enhancing insulin secretion and inhibiting glucagon secretion. SHR-2042 combined with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) promotes monomerization through the formation of micelles and improves oral absorption efficiency .

HY-111353

GPR120 Agonist 2	Free Fatty Acid Receptor	Metabolic Disease
GPR120 Agonist 2 (example 206) is a GPR120 agonist that can be uesd for the study of type II diabetes and diseases associated with poor glycemic control .

HY-N9911

1,5-Anhydro-D-mannitol	Others	Metabolic Disease
1,5-Anhydro-D-mannitol is the analogue of 1,5-Anhydrosorbitol (HY-113075), and can be used as an experimental control. 1,5-Anhydrosorbitol is a short-term marker for glycemic control.

HY-W768181

1,5-Anhydrosorbitol-13C6 1,5-Anhydro-D-glucitol-¹³C₆	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
1,5-Anhydrosorbitol- ¹³C₆ (1,5-Anhydro-D-glucitol- ¹³C₆) is the ¹³C-labeled 1,5-Anhydrosorbitol (HY-113075). 1,5-Anhydrosorbitol is a short-term marker for glycemic control.

HY-P11044

GEP12	GCGR Neuropeptide Y Receptor	Metabolic Disease
GEP12 is a GLP-1R/Y1-R/Y2-R tri-receptor agonist peptide with an EC₅₀ of 17.3 nM and an IC₅₀ of 19.2 nM for receptor binding. GEP12 may promote glycemic control and weight loss .

HY-112668B

Retagliptin hydrochloride SP2086 hydrochloride	Dipeptidyl Peptidase GCGR	Others
Retagliptin (SP2086) hydrochloride is a potent inhibitor of beta-amino acids and dipeptidyl peptidase-4 (DPP-4). Retagliptin (SP2086) hydrochloride inhibits type 2 diabetes and improves glycemic control by prolonging the action of intestinal hormones such as glucagon-like peptide-1 (GLP-1) .

HY-162513

DPP-4-IN-10	Dipeptidyl Peptidase	Metabolic Disease
DPP-4-IN-10 (compound 1) is a DPP-4 inhibitor. DPP-4-IN-10 is orally active. DPP-4-IN-10 blocks the degradation of GLP-1 and GIP, which may improve glycemic control in type 2 diabetes (T2MD) .

HY-15408R

Trelagliptin (Standard) SYR-472 (Standard)	Dipeptidyl Peptidase Reference Standards	Metabolic Disease
Trelagliptin (Standard) is the analytical standard of Trelagliptin. This product is intended for research and analytical applications. Trelagliptin (SYR-472) is a potent, orally active and highly selective DPP-4 inhibitor with an IC50 of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM) .

HY-125156

Dapagliflozin-3-O-β-D-glucuronide BMS-801576	Endogenous Metabolite	Metabolic Disease
Dapagliflozin-3-O-β-D-glucuronide (BMS-801576) is the metabolite of Dapagliflozin (HY-10450), and is formed in the liver and kidney by uridine diphosphate glucuronosyltransferase-1A9 (UGT1A9). Dapagliflozin is a selective inhibitor for SGLT2, that can be used to improve glycemic control and attenuate type 2 diabetes .

HY-15408AR

Trelagliptin succinate (Standard) SYR-472 succinate (Standard)	Reference Standards Dipeptidyl Peptidase	Metabolic Disease
Trelagliptin (succinate) (Standard) is the analytical standard of Trelagliptin (succinate). This product is intended for research and analytical applications. Trelagliptin (SYR-472) succinate is a potent, orally active and highly selective DPP-4 inhibitor with an IC₅₀ of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM) .

HY-13967A

AMG 837 sodium salt	Bacterial Free Fatty Acid Receptor	Infection Metabolic Disease
AMG 837 sodium salt is an orally active, selective GPR40/FFA1 agonist with an EC₅₀ of 1.5 nM against human GPR40. AMG 837 sodium salt stimulates insulin secretion in a glucose-dependent manner, and effectively improves glycemic control in both normal and diabetic rodent models . AMG 837 sodium salt binds to the BacA protein and impairs the survival and replication of Brucella. AMG 837 sodium salt can be used in research related to type 2 diabetes and brucellosis .

HY-14341

E-6837	5-HT Receptor	Metabolic Disease
E-6837 is a selective and orally active 5-HT₆ receptor ligand. E-6837 demonstrates partial agonism at a presumably silent rat 5-HT₆ receptor and full agonism at a constitutively active human 5-HT₆ receptor by monitoring the cAMP signaling pathway. E-6837 induces hypophagia, reduces fat mass and body weight, and improves glycemic control. E-6837 can be used for the research of obesity .

HY-113075R

1,5-Anhydrosorbitol (Standard) 1,5-Anhydro-D-glucitol (Standard)	Endogenous Metabolite Reference Standards	Metabolic Disease
1,5-Anhydrosorbitol (Standard) is the analytical standard of 1,5-Anhydrosorbitol. This product is intended for research and analytical applications. 1,5-Anhydrosorbitol is a short-term marker for glycemic control.

HY-105074R

Farglitazar (Standard) GI262570 (Standard); GI262570X (Standard)	Reference Standards PPAR	Metabolic Disease
Farglitazar (Standard) is the analytical standard of Farglitazar (HY-105074). This product is intended for research and analytical applications. Farglitazar is a PPARγ agonist that has significant therapeutic benefits such as glycemic control in type 2 diabetic patients.

HY-180527

SGLT2-IN-5	SGLT Dipeptidyl Peptidase	Metabolic Disease
SGLT2-IN-5 (Compound 99) is an orally active SGLT2 inhibitor with IC₅₀ values for SGLT2, SGLT1, and DPP4 of 0.8, 23, and 58 nM respectively. SGLT2-IN-5 controls blood sugar levels in diabetic rat models and increases the levels of active GLP-1. SGLT2-IN-5 can be used for the study of type 2 diabetes .

HY-P11604

C16 acid-I-{Lys(C10 diacid)}-KQELRRIGDEF	Phosphatase	Inflammation/Immunology
C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF is a cell-permeable and internalizable PTPN1/2 inhibitor, with IC₅₀ values of 107.6 nM and 3375 nM, respectively. C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF restores insulin signaling in HepG2 cells. C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF achieves glycemic control in db/db diabetic mice. C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF can be used in the research of type 2 diabetes .

Cat. No.	Product Name	Type

HY-W145665

Amylose	Biochemical Assay Reagents
Amylose is not a typical small-molecule ligand with a specific traditional receptor-binding target. It is a polysaccharide. In food science and biological systems, amylose can interact with proteins and free fatty acids through non-covalent forces like hydrophobic interactions and electrostatic interactions. For example, it can form a ternary complex with them, which is related to the structure and digestion of starch. It is widely studied in the fields of food science, carbohydrate metabolism, and is also relevant in research on controlling glycemic responses, as it affects starch digestion rate .

Amylose

Biochemical Assay Reagents

Amylose is not a typical small-molecule ligand with a specific traditional receptor-binding target. It is a polysaccharide. In food science and biological systems, amylose can interact with proteins and free fatty acids through non-covalent forces like hydrophobic interactions and electrostatic interactions. For example, it can form a ternary complex with them, which is related to the structure and digestion of starch. It is widely studied in the fields of food science, carbohydrate metabolism, and is also relevant in research on controlling glycemic responses, as it affects starch digestion rate .

HY-139201E

Poly-D-lysine hydrobromide (MW 150000-300000) PDLHB (MW 150000-300000)	Biochemical Assay Reagents
Poly-D-lysine hydrobromide (MW 150000-300000) is a synthetic polymer composed of D-lysine residues and is one of the most widely used matrices in neural cell culture applications. Poly-D-lysine hydrobromide (MW 150000-300000) can be used as a non-specific cell adhesion enhancer. Poly-D-lysine hydrobromide (MW 30000-70000) is an orally active CaSR agonist peptide that indirectly activates the 5-HT₃ receptor signaling pathway, delaying gastric emptying and thereby slowing the rate at which glucose enters the small intestine and is absorbed .

Poly-D-lysine hydrobromide (MW 150000-300000)

PDLHB (MW 150000-300000)

Biochemical Assay Reagents

Poly-D-lysine hydrobromide (MW 150000-300000) is a synthetic polymer composed of D-lysine residues and is one of the most widely used matrices in neural cell culture applications. Poly-D-lysine hydrobromide (MW 150000-300000) can be used as a non-specific cell adhesion enhancer. Poly-D-lysine hydrobromide (MW 30000-70000) is an orally active CaSR agonist peptide that indirectly activates the 5-HT₃ receptor signaling pathway, delaying gastric emptying and thereby slowing the rate at which glucose enters the small intestine and is absorbed .

HY-NP205

Glycated Albumin (Human)	Biochemical Assay Reagents
Glycated Albumin (Human) is an alternative marker for glycemic control. Glycated Albumin (Human) can react with glucose .

Cat. No.	Product Name	Target	Research Area

HY-P3463

Beinaglutide 1 Publications Verification GLP-1 (human)	GCGR	Metabolic Disease Inflammation/Immunology
Beinaglutide is a human GLP-1 polypeptide that shares almost 100% homology with human GLP-1 (7–36). Beinaglutide displays does-dependent effects in glycemic control, inhibiting food intake and gastric empty and promoting weight loss. Beinaglutide has the potential for the research of overweight/obesity and nonalcoholic steatohepatitis (NASH) .

HY-P10341

ZP3022	GCGR	Metabolic Disease
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .

HY-P10318

SHR-2042	GLP Receptor	Endocrinology
SHR-2042 is a selective agonist of the GLP-1 receptor.SHR-2042 improves glycemic control by activating the GLP-1 receptor, enhancing insulin secretion and inhibiting glucagon secretion. SHR-2042 combined with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) promotes monomerization through the formation of micelles and improves oral absorption efficiency .

HY-P11044

GEP12	GCGR Neuropeptide Y Receptor	Metabolic Disease
GEP12 is a GLP-1R/Y1-R/Y2-R tri-receptor agonist peptide with an EC₅₀ of 17.3 nM and an IC₅₀ of 19.2 nM for receptor binding. GEP12 may promote glycemic control and weight loss .

HY-P11604

C16 acid-I-{Lys(C10 diacid)}-KQELRRIGDEF	Phosphatase	Inflammation/Immunology
C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF is a cell-permeable and internalizable PTPN1/2 inhibitor, with IC₅₀ values of 107.6 nM and 3375 nM, respectively. C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF restores insulin signaling in HepG2 cells. C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF achieves glycemic control in db/db diabetic mice. C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF can be used in the research of type 2 diabetes .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W145665

Amylose	Human Gut Microbiota Metabolites Polysaccharides Classification of Application Fields Other Diseases Endogenous metabolite Disease Research Fields Saccharides Source Classification	Biochemical Assay Reagents Endogenous Metabolite
Amylose is not a typical small-molecule ligand with a specific traditional receptor-binding target. It is a polysaccharide. In food science and biological systems, amylose can interact with proteins and free fatty acids through non-covalent forces like hydrophobic interactions and electrostatic interactions. For example, it can form a ternary complex with them, which is related to the structure and digestion of starch. It is widely studied in the fields of food science, carbohydrate metabolism, and is also relevant in research on controlling glycemic responses, as it affects starch digestion rate .

HY-113075

1,5-Anhydrosorbitol 1 Publications Verification 1,5-Anhydro-D-glucitol	Immune System Disorder Classification of Application Fields Disease markers Endocrine diseases Metabolic Disease Endogenous metabolite Disease Research Fields Saccharides Source Classification	Endogenous Metabolite
1,5-Anhydrosorbitol is a short-term marker for glycemic control.

HY-N10423

Cubebin (-)-Cubebin	Structural Classification Classification of Application Fields Lignans Piperaceae Piper cubeba L.f. Phenylpropanoids Plants Inflammation/Immunology Disease Research Fields Source Classification	Cholinesterase (ChE) Bacterial Fungal Parasite p38 MAPK
Cubebin ((-)-Cubebin), a dibenzyl butyrolactone lignan, is an orally active AChE inhibitor. Cubebin binds to active sites of NF-κB, TNF-α, and TGF-β1 via hydrogen and hydrophobic interactions, obstructing critical residues to inhibit pro-inflammatory or renal fibrosis-related activity. Cubebin enhances p38 MAPK phosphorylation to increase tyrosinase gene expression, stimulating melanogenesis via elevated tyrosinase activity, expression, and mRNA levels. Cubebin reduces oxidative stress via enhanced endogenous antioxidant enzyme activity and inhibited lipid peroxidation, regulates lipid metabolism, improves glycemic control, and exerts renoprotective effects via reduced renal dysfunction markers and improved renal architecture. Cubebin shows antimicrobial activity. Cubebin exerts larvicidal activity against Angiostrongylus cantonensis larvae, with no cytotoxicity toward monkey or human cell lines or Caenorhabditis elegans. Cubebin can be used for the research of diabetic nephropathy, melanoma, colon adenocarcinoma, neuroangiostrongyliasis, Alzheimer’s disease (AD) and depression .

HY-N9911

1,5-Anhydro-D-mannitol	Natural Products Styrax obassia Siebold & Zucc. Styracaceae Plants Source Classification	Others
1,5-Anhydro-D-mannitol is the analogue of 1,5-Anhydrosorbitol (HY-113075), and can be used as an experimental control. 1,5-Anhydrosorbitol is a short-term marker for glycemic control.

HY-113075R

1,5-Anhydrosorbitol (Standard) 1,5-Anhydro-D-glucitol (Standard)	Structural Classification Immune System Disorder Disease markers Endocrine diseases Endogenous metabolite Saccharides Source Classification	Endogenous Metabolite Reference Standards
1,5-Anhydrosorbitol (Standard) is the analytical standard of 1,5-Anhydrosorbitol. This product is intended for research and analytical applications. 1,5-Anhydrosorbitol is a short-term marker for glycemic control.

Cat. No.	Product Name	Chemical Structure

HY-15408S

Trelagliptin-13C,d3
Trelagliptin-13C,d3 is a deuterated labeled Trelagliptin . Trelagliptin (SYR-472) is a potent, orally active and highly selective DPP-4 inhibitor with an IC₅₀ of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM) .

HY-W768181

1,5-Anhydrosorbitol-13C6
1,5-Anhydrosorbitol- ¹³C₆ (1,5-Anhydro-D-glucitol- ¹³C₆) is the ¹³C-labeled 1,5-Anhydrosorbitol (HY-113075). 1,5-Anhydrosorbitol is a short-term marker for glycemic control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Glycemic control

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products